Polo-like kinase 1 inhibition as a new therapeutic modality in therapy of cholangiocarcinoma

Anticancer Research

Volumn 31, Issue 10, 2011, Pages 3289-3299

  Thrum, Stephan ^a   Lorenz, Jana ^a   Mössner, Joachim ^a   Wiedmann, Marcus ^a,b  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b St Mary's Hospital   (Germany)

Author keywords

5 fluorouracil; BI 2536; Cholangiocarcinoma; Gemcitabine; Polo like kinase 1

Indexed keywords

4 (8 CYCLOPENTYL 7 ETHYL 5,6,7,8 TETRAHYDRO 5 METHYL 6 OXO 2 PTERIDINYLAMINO) 3 METHOXY N (1 METHYL 4 PIPERIDINYL)BENZAMIDE; FLUOROURACIL; GEMCITABINE; HISTONE H3; MESSENGER RNA; NVP AEW 541; POLO LIKE KINASE 1; PROTEIN KINASE B; PROTEIN P42; PROTEIN P44;

APOPTOSIS; ARTICLE; BILE DUCT CARCINOMA; CANCER CHEMOTHERAPY; CANCER INHIBITION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; GALLBLADDER CARCINOMA; HISTONE PHOSPHORYLATION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

CELL CYCLE; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; CHOLANGIOCARCINOMA; DEOXYCYTIDINE; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PTERIDINES; PYRIMIDINES; PYRROLES; RNA, MESSENGER;

EID: 80054753124     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Barr FA, Sillje HH and Nigg EA: Polo-like kinases and the orchestration of cell division. Nat Rev Mol Cell Biol 5: 429-440, 2004. (Pubitemid 38745493)
2. Glover DM, Hagan IM and Tavares AA: Polo-like kinases: a team that plays throughout mitosis. Genes Dev 12: 3777-3787, 1998. (Pubitemid 29024839)
3. Schoffski P: Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology. Oncologist 14: 559-570, 2009.
4. Steegmaier M, Hoffmann M, Baum A, Lenart P, Petronczki M, Krssak M, Gurtler U, Garin-Chesa P, Lieb S. Quant J, Grauert M, Adolf GR, Kraut N, Peters JM and Rettig WJ: BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo. Curr Biol 17: 316-322, 2007. (Pubitemid 46241881)
5. Wolf S, Lorenz J, Mossner J and Wiedmann M: Treatment of biliary tract cancer with NVP-AEW541: mechanisms of action and resistance. World J Gastroenterol 16: 156-166, 2010.
6. Purdum PP, 3rd, Ulissi A, Hylemon PB, Shiffman ML and Moore EW: Cultured human gallbladder epithelia. Methods and partial characterization of a carcinoma-derived model. Lab Invest 68: 345-353, 1993. (Pubitemid 23097656)
7. Knuth A, Gabbert H, Dippold W, Klein O, Sachsse W, Bitter-Suermann D, Prellwitz W and Meyer zum Buschenfelde KH: Biliary adenocarcinoma. Characterisation of three new human tumor cell lines. J Hepatol 1: 579-596, 1985. (Pubitemid 15015131)
8. Pignochino Y, Sarotto I, Peraldo-Neia C, Penachioni JY, Cavalloni G, Migliardi G, Casorzo L, Chiorino G, Risio M, Bardelli A, Aglietta M and Leone F: Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas. BMC Cancer 10: 631, 2010.
9. Kusaka Y, Tokiwa T and Sato J: Establishment and characterization of a cell line from a human cholangiocellular carcinoma. Res Exp Med (Berl) 188: 367-375, 1988.
10. Enjoji M, Sakai H, Nawata H, Kajiyama K and Tsuneyoshi M: Sarcomatous and adenocarcinoma cell lines from the same nodule of cholangiocarcinoma. In Vitro Cell Dev Biol Anim 33: 681-683, 1997.
11. Shimizu Y, Demetris AJ, Gollin SM, Storto PD, Bedford HM, Altarac S, Iwatsuki S, Herberman RB and Whiteside TL: Two new human cholangiocarcinoma cell lines and their cytogenetics and responses to growth factors, hormones, cytokines or immunologic effector cells. Int J Cancer 52: 252-260, 1992.
12. International Conference on Tumor Necrosis Factor and Related Cytotoxins. September 14-18, 1987, Heidelberg, Federal Republic of Germany. Abstracts. Immunobiology 175: 1-143, 1987.
13. Saijyo S, Kudo T, Suzuki M, Katayose Y, Shinoda M, Muto T, Fukuhara K, Suzuki T and Matsuno S: Establishment of a new extrahepatic bile duct carcinoma cell line, TFK-1. Tohoku J Exp Med 177: 61-71, 1995.
14. Pfaffl MW, Horgan GW and Dempfle L: Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res 30: e36, 2002.
15. Berenbaum MC: Criteria for analyzing interactions between biologically active agents. Adv Cancer Res 35: 269-335, 1981.
16. Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, Roughton M and Bridgewater J: Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362: 1273-1281, 2010.
17. Sharma A, Dwary AD, Mohanti BK, Deo SV, Pal S, Sreenivas V, Raina V, Shukla NK, Thulkar S, Garg P and Chaudhary SP: Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study. J Clin Oncol 28: 4581-4586, 2010.
18. Wiedmann MW and Mossner J: Molecular targeted therapy of biliary tract cancer - results of the first clinical studies. Curr Drug Targets 11: 834-850, 2010.
19. Liu X, Lei M and Erikson RL: Normal cells, but not cancer cells, survive severe Plk1 depletion. Mol Cell Biol 26: 2093-2108, 2006. (Pubitemid 43346913)
20. Luo J, Emanuele MJ, Li D, Creighton CJ, Schlabach MR, Westbrook TF, Wong KK and Elledge SJ: A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 137: 835-848, 2009.
21. Nappi TC, Salerno P, Zitzelsberger H, Carlomagno F, Salvatore G and Santoro M: Identification of Polo-like kinase 1 as a potential therapeutic target in anaplastic thyroid carcinoma. Cancer Res 69: 1916-1923, 2009.
22. Renner AG, Dos Santos C, Recher C, Bailly C, Creancier L, Kruczynski A, Payrastre B and Manenti S: Polo-like kinase 1 is overexpressed in acute myeloid leukemia and its inhibition preferentially targets the proliferation of leukemic cells. Blood 114: 659-662, 2009.
23. Grinshtein N, Datti A, Fujitani M, Uehling D, Prakesch M, Isaac M, Irwin MS, Wrana JL, Al-Awar R and Kaplan DR: Small molecule kinase inhibitor screen identifies polo-like kinase 1 as a target for neuroblastoma tumor-initiating cells. Cancer Res 71: 1385-1395, 2011.
24. Holtrich U, Wolf G, Brauninger A, Karn T, Bohme B, Rubsamen-Waigmann H and Strebhardt K: Induction and down-regulation of PLK, a human serine/threonine kinase expressed in proliferating cells and tumors. Proc Natl Acad Sci USA 91: 1736-1740, 1994. (Pubitemid 24080280)
25. Jackson MW, Agarwal MK, Yang J, Brass P, Uchiumi T, Agarwal ML, Stark GR and Taylor WR: p130/p107/p105Rb-dependent transcriptional repression during DNA-damage-induced cell-cycle exit at G2. J Cell Sci 118: 1821-1832, 2005. (Pubitemid 40723827)
26. Martin BT and Strebhardt K: Polo-like kinase 1: target and regulator of transcriptional control. Cell Cycle 5: 2881-2885, 2006. (Pubitemid 44953940)
27. Laoukili J, Kooistra MR, Bras A, Kauw J, Kerkhoven RM, Morrison A, Clevers H and Medema RH: FOXM1 is required for execution of the mitotic programme and chromosome stability. Nat Cell Biol 7: 126-136, 2005. (Pubitemid 40268127)
28. Krupczak-Hollis K, Wang X, Kalinichenko VV, Gusarova GA, Wang IC, Dennewitz MB, Yoder HM, Kiyokawa H, Kaestner KH and Costa RH: The mouse Forkhead Box ml transcription factor is essential for hepatoblast mitosis and development of intrahepatic bile ducts and vessels during liver morphogenesis. Dev Biol 276: 74-88, 2004. (Pubitemid 39452847)
29. Fu Z, Malureanu L, Huang J, Wang W, Li H, van Deursen JM, Tindall DJ and Chen J: Plk1-dependent phosphorylation of FOXMl regulates a transcriptional programme required for mitotic progression. Nat Cell Biol 10: 1076-1082, 2008.
30. Pellegrino R, Calvisi DF, Ladu S, Ehemann V, Staniscia T, Evert M, Dombrowski F, Schirmacher P and Longerich T: Oncogenic and tumor suppressive roles of polo-like kinases in human hepatocellular carcinoma. Hepatology 51: 857-868, 2010.
31. Gilmartin AG, Bleam MR, Richter MC, Erskine SG, Kruger RG, Madden L, Hassler DF, Smith GK, Gontarek RR, Courtney MP, Sutton D, Diamond MA, Jackson JR and Laquerre SG: Distinct concentration-dependent effects of the polo-like kinase 1-specific inhibitor GSK461364A, including differential effect on apoptosis. Cancer Res 69: 6969-6977, 2009.
32. Mross K, Frost A, Steinbild S, Hedbom S, Rentschier J, Kaiser R, Rouyrre N, Trommeshauser D, Hoesl CE and Munzert G: Phase I dose escalation and pharmacokinetic study of BI 2536, a novel polo-like kinase 1 inhibitor, in patients with advanced solid tumors. J Clin Oncol 26: 5511-5517, 2008.
33. Hofheinz RD, Al-Batran SE, Hochhaus A, Jager E, Reichardt VL, Fritsch H, Trommeshauser D and Munzert G: An open-label, phase I study of the polo-like kinase-1 inhibitor, BI 2536, in patients with advanced solid tumors. Clin Cancer Res 16: 4666-4674, 2010.
34. Ellis P, Chu Q, Leighl N, Laurie S, Trommeshauser D, Hanft G, Munzert G and Gyorffy S: A phase I dose escalation trial of BI 2536, a novel Plk1 inhibitor, with standard dose pemetrexed in previously treated advanced or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol 26: abstract 8115, 2008.
35. Pandha H, Protheroe A, Wylie J, Parker C, Chambers J, Bell S and Munzert G: An open label phase II trial of BI 2536, a novel Plk1 inhibitor, in patients with metastatic hormone-refractory prostate cancer (HRPC). J Clin Oncol 26: abstract 14547, 2008.
36. Mross K, Dittrich C, Aulitzky W, Strumberg D, Schütte J, Schmid R, Hollerbach S, Merger M, Munzert G and Scheulen M: A randomized phase II trial of the novel Polo-like kinase 1 inhibitor BI 2536 in chemonaïve patients with unresectable advanced pancreatic cancer: a study in cooperation with the CESAR network of investigators. Ann Oncol 19: 163 (abstract), 2008.
37. Sebastian M, Reck M, Waller CF, Kortsik C, Frickhofen N, Schuler M, Fritsch H, Gaschler-Markefski B, Hanft G, Munzert G and von Pawel J: The efficacy and safety of BI 2536, a novel PLKl inhibitor, in patients with stage IIIB/IV non-small cell lung cancer who had relapsed after, or failed, chemotherapy: results from an open-label, randomized phase II clinical trial. J Thorac Oncol 5: 1060-1067, 2010.
38. Schoffski P, Blay JY, De Greve J, Brain E, Machiels JP, Soria JC, Sleijfer S, Wolter P, Ray-Coquard I, Fontaine C, Munzert G, Fritsch H, Hanft G, Aerts C, Rapion J, Allgeier A, Bogaerts J and Lacombe D: Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI). Eur J Cancer 46: 2206-2215, 2010.
39. Eckel F and Schmid RM: Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. Br J Cancer 96: 896-902, 2007. (Pubitemid 46452283)
40. Baserga R: The insulin-like growth factor-I receptor as a target for cancer therapy. Expert Opin Ther Targets 9: 753-768, 2005.
41. Sachdev D and Yee D: Disrupting insulin-like growth factor signaling as a potential cancer therapy. Mo Cancer Ther 6: 1-12, 2007. (Pubitemid 46206663)
42. Larsson O, Girnita A and Girnita L: Role of insulin-like growth factor 1 receptor signalling in cancer. Br J Cancer 92: 2097-2101, 2005. (Pubitemid 40966242)
43. Reinmuth N, Liu W, Fan F, Jung YD, Ahmad SA, Stoeltzing O, Bucana CD, Radinsky R and Ellis LM: Blockade of insulin-like growth factor I receptor function inhibits growth and angiogenesis of colon cancer. Clin Cancer Res 8: 3259-3269, 2002. (Pubitemid 35155039)
44. Stoeltzing O, Liu W, Reinmuth N, Fan F, Parikh AA, Bucana CD, Evans DB, Semenza GL and Ellis LM: Regulation of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and angiogenesis by an insulin-like growth factor-I receptor autocrine loop in human pancreatic cancer. Am J Pathol 163: 1001-1011, 2003. (Pubitemid 37040136)
45. Goad DL, Rubin J, Wang H, Tashjian AH Jr. and Patterson C: Enhanced expression of vascular endothelial growth factor in human SaOS-2 osteoblast-like cells and murine osteoblasts induced by insulin-like growth factor I. Endocrinology 137: 2262-2268, 1996. (Pubitemid 26155757)
46. Yee D: Targeting insulin-like growth factor pathways. Br J Cancer 94: 465-468, 2006.
47. Garcia-Echeverria C, Pearson MA, Marti A, Meyer T, Mestan J, Zimmermann J, Gao J, Brueggen J, Capraro HG, Cozens R, Evans DB, Fabbro D, Furet P, Porta DG, Liebetanz J, Martiny-Baron G, Ruetz S and Hofmann F: In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase. Cancer Cell 5: 231-239, 2004. (Pubitemid 38402115)